[EN] 1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2 [FR] DÉRIVÉS 1,2,3,5-TÉTRAHYDRO-IMIDAZO [1,2-C]PYRIMIDINE UTILES POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES MÉDIÉS PAR LA LP-PLA2
[EN] 1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2 [FR] DÉRIVÉS 1,2,3,5-TÉTRAHYDRO-IMIDAZO [1,2-C]PYRIMIDINE UTILES POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES MÉDIÉS PAR LA LP-PLA2
申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US20140213599A1
公开(公告)日:2014-07-31
The present invention relates to novel compounds that inhibit Lp-PLA
2
activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA
2
, for example atherosclerosis, Alzheimer's disease.
[EN] 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS<br/>[FR] INHIBITEURS DE LA PHOSPHOLIPASE ASSOCIÉE AUX LIPOPROTÉINES A2 (LP-PLA2) À BASE DE 2,3-DIHYDRO-IMIDAZOL[1,2-C]PYRIMIDIN-5(1 H)-ONE
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2014114694A1
公开(公告)日:2014-07-31
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US09051325B2
公开(公告)日:2015-06-09
The present invention relates to bicyclic[5,6]imidazo pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
In one aspect, this invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof,
wherein different R groups are defined in the patent application.
2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US20150361082A1
公开(公告)日:2015-12-17
The present invention relates to novel compounds that inhibit Lp-PLA
2
activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA
2
, for example atherosclerosis, Alzheimer's disease.